Multimodality imaging for improved detection of epileptogenic foci in tuberous sclerosis complex

Neurology

Volumn 54, Issue 10, 2000, Pages 1976-1984

  Asano, E ^b   Chugani, Diane C ^a   Muzik, O ^b   Shen, C ^b   Juhasz C ^b   Janisse, J ^b   Ager, J ^b   Canady, A ^b   Shah, J R ^b   Shah, A K ^b   Watson, C ^b   Chugani, H T ^b  

^a CHILDREN'S HOSPITAL OF MICHIGAN   (United States)

^b NONE

Author keywords

Epilepsy surgery; Neuroimaging; PET; Quinolinic acid; Serotonin; Tuberous sclerosis complex; 11C methyl L tryptophan

Indexed keywords

FLUORODEOXYGLUCOSE F 18; N METHYLTRYPTOPHAN C 11; TRACER; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CHILD; CLINICAL ARTICLE; DIAGNOSTIC VALUE; ELECTROENCEPHALOGRAPHY; EPILEPSY; EPILEPTIC FOCUS; HUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TUBEROUS SCLEROSIS;

EID: 0034705014     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.54.10.1976     Document Type: Article

References (47)

1. van Slegtenhorst M, de Hoogt R, Hermans C, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science 1997;277:805-808.
2. The European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell 1993;75:1305-1315.
3. Gomez MR. Neurologic and psychiatric features. In: Gomez MR, ed. Tuberous sclerosis. 2nd ed. New York: Raven Press, 1988:21-36.
4. Webb DW, Fryer AE, Osborne JP. Morbidity associated with tuberous sclerosis: a population study. Dev Med Child Neurol 1996;38:146-155.
5. Avellino AM, Berger MS, Rostomily RC, Shaw CM, Ojemann GA. Surgical management and seizure outcome in patients with tuberous sclerosis. J Neurosurg 1997;87:391-396.
6. Bebin EM, Kelly PJ, Gomez MR. Surgical treatment for epilepsy in cerebral tuberous sclerosis. Epilepsia 1993;34:651-657.
7. Guerreiro MM, Andermann F, Andermann E, et al. Surgical treatment of epilepsy in tuberous sclerosis: strategies and results in 18 patients. Neurology 1998;51:1263-1269.
8. Fukushima K, Inoue Y, Fujiwara T, Yagi K. Long-term course of West syndrome associated with tuberous sclerosis. Epilepsia 1998;39(suppl 5):50-54.
9. Takanashi J, Sugita K, Fujii K, Niimi H. MR evaluation of tuberous sclerosis: increased sensitivity with fluid-attenuated inversion recovery and relation to severity of seizures and mental retardation. AJNR Am J Neuroradiol 1995;16:1923-1928.
10. Rintahaka PJ, Chugani HT. Clinical role of positron emission tomography in children with tuberous sclerosis complex. J Child Neurol 1997;12:42-52.
11. Diksic M, Nagahiro S, Sourkes TL, Yamamoto YL. A new method to measure brain serotonin synthesis in vivo. I. Theory and basic data for a biological model. J Cereb Blood Flow Metab 1990;10:1-12.
12. Chugani DC, Muzik O, Chakraborty P, Mangner T, Chugani HT. Human brain serotonin synthesis capacity measured in vivo with alpha-[C-11]methyl-L-tryptophan. Synapse 1998;28: 33-43.
13. Muzik O, Chugani DC, Chakraborty P, Mangner T, Chugani HT. Analysis of [C-11]alpha-methyl-tryptophan kinetics for the estimation of serotonin synthesis rate in vivo. J Cereb Blood Flow Metab 1997;17:659-669.
14. 11C]methyl-L-tryptophan positron emission tomography. Ann Neurol 1998;44:858-866.
15. Roach ES, Gomez MR, Northrup H. Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria. J Child Neurol 1998;13:624-628.
16. Chugani HT, Phelps ME, Mazziotta JC. Positron emission tomography study of human brain functional development. Ann Neurol 1987;22:487-497.
17. Wolf WA, Kuhn DM. Uptake and release of tryptophan and serotonin: an HPLC method to study the flux of endogenous 5-hydroxyindoles through synaptosomes. J Neurochem 1986; 46:61-67.
18. Woodard HQ, Bigler RE, Freed B. Expression of tissue isotope distribution. J Nucl Med 1975;16:958-959. Letter.
19. Szelies B, Herholz K, Heiss WD, et al. Hypometabolic cortical lesions in tuberous sclerosis with epilepsy: demonstration by positron emission tomography. J Comput Assist Tomogr 1983; 7:946-953.
20. Pietrzyk U, Herholz K, Fink G, et al. An interactive technique for three-dimensional image registration: validation for PET, SPECT, MRI and CT brain studies. J Nucl Med 1994;35:2011-2018.
21. Kennedy DN, Filipek PA, Caviness VS Jr. Anatomic segmentation and volumetric calculations in nuclear magnetic resonance imaging. Trans Med Imaging 1989;8:1-7.
22. Javoy-Agid F, Scatton B, Ruberg M, et al. Distribution of monoaminergic, cholinergic, and GABAergic markers in the human cerebral cortex. Neuroscience 1989;29:251-259.
23. Metz CE. Basic principles of ROC analysis. Semin Nucl Med 1978;8:283-298.
24. Gatrell AC, Bailey TC. Interactive spatial data analysis in medical geography. Soc Sci Med 1996;42:843-855.
25. Kato T, Yamanouchi H, Sugai K, Takashima S. Improved detection of cortical and subcortical tubers in tuberous sclerosis by fluid-attenuated inversion recovery MRI. Neuroradiol 1997;39:378-380.
26. Huttenlocher PR, Heydemann PT. Fine structure of cortical tubers in tuberous sclerosis: a Golgi study. Ann Neurol 1984; 16:595-602.
27. Machado-Salas JP. Abnormal dendritic patterns and aberrant spine development in Bourneville's disease - a Golgi survey. Clin Neuropathol 1984;3:52-58.
28. Chadwick D, Jenner P, Reynolds EH. Serotonin metabolism in human epilepsy: the influence of anticonvulsant drugs. Ann Neurol 1977;1:218-224.
29. Young SN, Gauthier S, Anderson GM, Purdy WC. Tryptophan, 5-hydroxyindoleacetic acid and indoleacetic acid in human cerebrospinal fluid: interrelationships and the influence of age, sex, epilepsy and anticonvulsant drugs. J Neurol Neurosurg Psychiatry 1980;43:438-445.
30. Shaywitz BA, Cohen DJ, Bowers MB. Reduced cerebrospinal fluid 5-hydroxyindoleacetic acid and homovanillic acid in children with epilepsy. Neurology 1975;25:72-79.
31. Chugani DC, Muzik O, Behen M, et al. Developmental changes in brain serotonin synthesis capacity in autistic and nonautistic children. Ann Neurol 1999;45:287-295.
32. Hwang PA, Otsubo H, Koo BK, et al. Infantile spasms: cerebral blood flow abnormalities correlate with EEG, neuroimaging, and pathologic findings. Pediatr Neurol 1996;14:220-225.
33. Kothare SV, VanLandingham K, Armon C, Luther JS, Friedman A, Radtke RA. Seizure onset from periventricular nodular heterotopias: depth-electrode study. Neurology 1998;51: 1723-1727.
34. Richardson EP Jr. Pathology of tuberous sclerosis. Neuropathologic aspects. Ann NY Acad Sci 1991;615:128-139.
35. Li LM, Dubeau F, Andermann F, et al. Periventricular nodular heterotopia and intractable temporal epilepsy: poor outcome after temporal lobe resection. Ann Neurol 1997;41:662-668.
36. Palmini A, Gambardella A, Andermann F, et al. Intrinsic epileptogenicity of human dysplastic cortex as suggested by corticography and surgical results. Ann Neurol 1995;37:476-487.
37. Louw D, Sutherland GR, Glavin GB, Girvin J. A study of monoamine metabolism in human epilepsy. Can J Neurol Sci 1989;16:394-397.
38. Pintor M, Mefford IN, Hutter I, Pocotte SL, Wyler AR, Nadi NS. Levels of biogenic amines, their metabolites, and tyrosine hydroxylase activity in the human epileptic temporal cortex. Synapse 1990;5:152-156.
39. Trottier S, Evrard B, Vignal JP, Scarabin JM, Chauvel P. The serotonergic innervation of the cerebral cortex in man and its changes in focal cortical dysplasia. Epilepsy Res 1996;25:79-106.
40. Chugani DC, Heyes MP, Kuhn DM, Chugani HT. Evidence α[C-11]methyl-L-tryptophan PET traces tryptophan metabolism via the kynurenine pathway in tuberous sclerosis complex. Soc Neurosci Abstracts 1998;24:1757. Abstract.
41. Haber R, Bessette D, Hulihan-Giblin B, Durcan MJ, Goldman D. Identification of tryptophan 2,3-dioxygenase RNA in rodent brain. J Neurochem 1993;60:1159-1162.
42. Yamazaki F, Kuroiwa T, Takikawa O, Kido R. Human indolylamine 2,3-dioxygenase. Its tissue distribution, and characterization of the placental enzyme. Biochem J 1985;230: 635-638.
43. Lapin IP. Convulsant action of intracerebroventricularly administered 1-kynurenine sulphate, quinolinic acid and other derivatives of succinic acid, and effects of amino acids: structure-activity relationships. Neuropharmacology 1982;21: 1227-1233.
44. Perkins MN, Stone TW. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res 1982;247: 184-187.
45. Schwarcz R, Brush GS, Foster AC, French ED. Seizure activity and lesions after intrahippocampal quinolinic acid injection. Exp Neurol 1984;84:1-17.
46. Feldblum S, Rougier A, Loiseau H, et al. Quinolinic-phosphoribosyl transferase activity is decreased in epileptic human brain tissue. Epilepsia 1988;29:523-529.
47. Heyes MP, Wyler AR, Devinsky O, Yergey JA, Markey SP, Nadi NS. Quinolinic acid concentrations in brain and cerebrospinal fluid of patients with intractable complex partial seizures. Epilepsia 1990;31:172-177.